Antibiotic prescribing for respiratory tract infection in patients with suspected and proven COVID-19: results from an antibiotic point prevalence survey in Scottish hospitals

R. Andrew Seaton1,2*, Lesley Cooper2, Cheryl L. Gibbons3, William Malcolm4, Brian Choo-Kang5, David Griffith6, Stephanie Dundas7, Suzanne Brittain8, Kayleigh Hamilton9, Danielle Jeffreys10, Rachel McKinney11, Debbie Guthrie12 and Jacqueline Sneddon2

1Infectious Diseases Unit, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF, UK; 2Scottish Antimicrobial Prescribing Group, Healthcare Improvement Scotland, Delta House, 48 West Nile Street, Glasgow, G1 2NP, UK; 3Public Health Scotland, NHS National Services Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QE, UK; 4ARHAI Scotland, NHS National Services Scotland, Meridian Court, 5 Cadogan Street, Glasgow, G2 6QE, UK; 5Respiratory Medicine Unit, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, G4 0SF, UK; 6Department of Microbiology, Victoria Infirmary, Hayfield Road, Kirkcaldy, KY2 5AH, UK; 7Infection Unit, University Hospital Monklands, Monkscourt Avenue, Airdrie, ML6 OJS, UK; 8Antimicrobial Management Team, Aberdeen Royal Infirmary, Foresterhill Health Campus, Foresterhill Road, Aberdeen, AB25 2ZU, UK; 9Antimicrobial Management Team, University Hospital Crosshouse, Kilmaurs Road, Crosshouse, Kilmarnock, KA2 0BE, UK; 10Respiratory Medicine Unit, Raigmore Hospital, Old Perth Road, Inverness, IV2 3UJ; 11Regional Infectious Diseases Unit, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK; 12Pharmacy Department, Ninewells Hospital, James Arrott Drive, Dundee, DD2 1SG, UK

*Corresponding author. R. Andrew Seaton, E-mail: andrew.seaton@ggc.scot.nhs.uk

Received 27 January 2021; accepted 30 April 2021

Background: Bacterial co-infection is infrequently observed with SARS-CoV-2/COVID-19 infection outside of critical care, however, antibiotics are commonly prescribed.

Objectives: To examine factors associated with antibiotic prescribing for suspected respiratory tract infection (RTI) and evaluate the nature and dynamics of prescribing in hospitalized patients with suspected and proven COVID-19 infection.

Methods: An antibiotic point prevalence survey in hospitalized adult patients was conducted in designated COVID-19 clinical areas (including critical care) in 15 Scottish hospitals. Antibiotics prescribed for RTI and factors associated with prescribing were investigated.

Results: Of 820 surveyed patients, 272 (prevalence 33.3%) received antibiotics for suspected RTI on the survey day and 58.8% were SARS-CoV-2 positive. Antibiotics were empirical in 91.9% and amoxicillin (24.6%), doxycycline (20.5%) and co-amoxiclav (15%) were most frequently prescribed. Oral antibiotics were prescribed in 54.5% and duration was recorded in 76.7% on wards for a median of 5 days. IV to oral switch occurred after a median of 2 days. Prescribing for RTI was independently and positively associated with COPD/chronic lung disease, purulent/bloody sputum, abnormal chest X-ray, and CRP ≥100 mg/L. Probable and definite hospital-acquired COVID-19 and diabetes were associated with a lower odds of receiving an antibiotic for RTI.

Conclusions: Antibiotic prescribing for suspected RTI was commonly observed and predominantly empirical in suspected or proven COVID-19. Initiatives to reinforce stewardship principles including clinical review, effective use of microbiological diagnostics and better understanding of the role of biomarkers are central to further limit unnecessary antibiotic therapy in COVID-19.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Lower respiratory tract infection (RTI) is the commonest indication for antibiotics in hospitalized adults in Scotland, accounting for more than one in three antibiotic prescriptions. Limiting unnecessary antibiotic prescribing in viral or low-risk bacterial RTI is a key focus for antimicrobial stewardship (AMS). The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the COVID-19 pandemic has significantly challenged AMS efforts as empirical antibiotic prescribing has become widespread. In March 2020, the Scottish Antimicrobial Prescribing Group (SAPG) developed and disseminated AMS advice via local Antimicrobial Management Teams (AMTs) cautioning against routine antibiotic use in COVID-19 without clinical or radiological evidence of bacterial infection. The advice also promoted the judicious use of short duration (5 days) narrow-spectrum antibiotics such as doxycycline and amoxicillin in patients with clinical suspicion of pneumonia or bacterial lower RTI. A point prevalence survey (PPS) of antimicrobial use was conducted at the time of peak SARS-CoV-2 clinical activity in patients with suspected or proven COVID-19 infection in Scottish hospitals. We observed a 45.0% prevalence of antibiotic prescribing in this population, with suspected RTI being the commonest recorded indication (73.9%). Herein we explore variables associated with antibiotic prescribing specifically in this subset of the population with suspected RTI and in addition examine key elements of antibiotic prescribing, including AMS measures not described in the previous report.

Patients and methods

Study design and inclusion criteria

A PPS of hospitalized adult patients with suspected or confirmed COVID-19 was conducted between 20 and 30 April 2020 in designated COVID-19 clinical areas (wards and critical care units) across 15 NHS Scotland hospitals. PPS methodology has been described in full elsewhere. The diagnosis of RTI was as recorded in case records and included any of pneumonia (hospital-acquired, community-acquired, aspiration or ventilator-associated), infective exacerbation of COPD or other lower RTI. Data were collected from handwritten and electronic medical and laboratory records and prescription charts.

Data definitions

Probable nosocomial COVID-19 and definite nosocomial COVID-19 were defined as a positive SARS-CoV-2 test, 8–14 days and more than 14 days following admission, respectively. Information on antibiotics prescribed for suspected RTI on the day of data collection including start date, route, and whether IV to oral switch had occurred was recorded. Prescribing was recorded as empirical (prior to microbiological confirmation) or directed (following microbiological confirmation). Specific microbiological results were not collected. Potential factors influencing antibiotic prescribing were recorded as were descriptive clinical data, including: presence and nature of sputum production (grouped as ‘purulent/bloody’ if recorded as green, brown or bloody sputum); C-reactive protein (CRP) value; and chest X-ray results were grouped as normal or abnormal (including COVID-19 compatible, indeterminate, pneumonia or other abnormal). Other non-infection clinical management and advanced care planning were recorded where available. Anonymized data were sent to the core survey team for curatation, validation and analysis.

Descriptive analysis

Analyses included patients with a SARS-CoV-2 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) test result. Prevalence estimates with 95% confidence intervals (95% CI) were calculated and frequency tables of survey population and prescribing characteristics were produced. Patients with missing data were excluded from denominators. Data were examined for the whole patient population and comparisons were made between those prescribed antibiotics for RTI and those who did not receive an antibiotic on the day of data collection. Those on medical or elderly care wards (combined as ‘wards’) were compared with those on high dependency and ICUs (combined as ‘critical care’). Pearson’s Chi square tests with a continuity correction or Fisher’s Exact tests were used to compare percentages between two groups and determine if significantly different. A Mann-Whitney U test was used to compare median ages between groups. Median durations were presented with range (minimum to maximum) and interquartile range (IQR). Statistical significance was set at \( P < 0.05 \). All analyses were carried out using R (version 3.5.1).

Statistical analysis

Univariable and multivariable regression analyses were conducted to identify factors associated with prescribing of antibiotics for RTI on the day of data collection. A survey-weighted binomial model was used (which accounted for clustering of beds within wards).

Univariable factors were screened and those with \( P \) values below 0.3 were included in a backward elimination and forward stepwise approach to select the most parsimonious multivariable model. Statistical significance was set at \( P < 0.05 \). A category-level \( P \) value (using the Wald test), odds ratios (OR) and 95% CI were calculated for each factor in the final model.

Ethics approval

Local governance processes for audit/survey of clinical practice were followed. No patient identifiers were collected by the central survey team and there were no interventions or patient contact during the survey.

Results

Of 820 patients surveyed, 272 received at least one antibiotic for suspected RTI on the survey day (prevalence 33.3%, 95% CI = 30.1–36.6). The majority of treated RTI patients (69.5%) were managed in a medical ward, 13.2% in elderly care and 17.3% in critical care. On the day of data collection 160 (58.8%) were SARS-CoV-2 positive. Clinical and demographic characteristics of those receiving antibiotics for suspected RTI are shown in Table 1. A total of 347 antibiotics were prescribed in 272 patients. Most frequent were amoxicillin (24.6%), doxycycline (20.5%), amoxicillin/clavulanate (15%) and piperacillin/tazobactam (6.9%). Macrolides were prescribed in 6.8% and fluoroquinolones and cephalosporins were prescribed 3.4% and 0.3%, respectively. Meropenem and piperacillin/tazobactam comprised 21.7% and 18.3% of antibiotics prescribed in critical care units and 1.0% and 4.5% of those in wards, respectively (Table 2). Single agent therapy was used in 74.9%, whilst 22.5% received dual, and 2.6% received triple therapy (Table 3). Antibiotic prescribing for RTI on the day of data collection was empirical in 91.9% of patients (Table 3). Overall, 146 (54.5%) patients with suspected RTI were receiving oral antibiotic therapy (64.1% on wards and 6.7% in critical care). Planned duration of oral antibiotic therapy was recorded in 76.7% of patients on wards and median recorded planned duration of oral antibiotic therapy was 5 days (range 2–10, IQR 3–7 days). Patients who had switched
from IV to oral did so after a median IV duration of 2 days (range 1–18, IQR 1–4 days). Of those receiving IV therapy, the median duration of IV antibiotics was 2 days (range 1–26, IQR 2–3) on wards and 3 days (range 1–13, IQR 2–6) on critical care units.

Clinical variables were examined for an association with antibiotic prescribing for RTI (versus no antibiotic prescription) on the day of data collection (Table 4). In a multivariable logistic regression analysis, prescribing for RTIs was independently and positively associated with COPD/chronic lung disease, purulent/bloody sputum, an abnormal chest X-ray, and CRP ≥ 100 mg/L. SARS-CoV-2 RT-PCR-positive, probable and definite hospital-acquired COVID-19 and diabetes were all associated with lower odds of receiving an antibiotic for RTI on the day of survey (Table 5).

### Table 1. Characteristics of the population prescribed antibiotics for respiratory tract infection (RTI)

| Patient characteristics | Total surveyed patients | Total surveyed with characteristic | Percentage |
|-------------------------|-------------------------|-----------------------------------|------------|
| COVID status            |                         |                                   |            |
| SARS-CoV-2 positive test| 272                     | 160                               | 58.8       |
| Probable or definite nosocomial COVID-19 | 272 | 16 | 5.9 |
| COVID-19 suspected on admission | 272 | 247 | 90.8 |
| Demographics            |                         |                                   |            |
| Age, median (range)     | 68.5 years (range 17–95, IQR 56–79) |                                   |            |
| Sex (% male)            | 272                     | 138                               | 50.7       |
| Location                |                         |                                   |            |
| Care home resident      | 272                     | 25                                | 9.2        |
| Ward type—Critical care | 272 | 47 | 17.3 |
| Ward type—Elderly      | 272                     | 36                                | 13.2       |
| Ward type—Medical      | 272                     | 189                               | 69.5       |
| Comorbidities           |                         |                                   |            |
| Asthma                  | 272                     | 35                                | 12.9       |
| Cardiovascular disease  | 272                     | 87                                | 32.0       |
| COPD/chronic lung disease | 271 | 76 | 28.0 |
| Diabetes                | 272                     | 49                                | 18.0       |
| Hypertension            | 271                     | 106                               | 39.1       |
| Immunocompromised       | 272                     | 37                                | 13.6       |
| Long term renal dialysis| 272 | 5 | 1.8 |
| Morbid obesity          | 267                     | 20                                | 7.5        |
| Other chronic condition | 270                     | 165                               | 61.1       |
| Other                   |                         |                                   |            |
| Other suspected infection | 271 | 140 | 51.7 |
| Penicillin allergy      | 272                     | 42                                | 15.4       |
| Diagnostics/clinical signs |                   |                                   |            |
| Abnormal chest X-ray    | 272                     | 224                               | 82.4       |
| CRP ≥ 100 mg/L          | 269                     | 130                               | 48.3       |
| Purulent/bloody sputum  | 272                     | 40                                | 14.7       |
| Management              |                         |                                   |            |
| Clinical therapeutic trial | 272 | 39 | 14.3 |
| Supplemental oxygen     | 272                     | 158                               | 58.1       |
| Treatment escalation<sup>a</sup> | 229 | 110 | 48.0 |
| DNAR recorded           | 271                     | 132                               | 48.7       |

COPD, chronic obstructive pulmonary disease and other chronic lung disease; DNAR, do not attempt cardiopulmonary resuscitation order; CRP, C-reactive protein.

<sup>a</sup>Treatment escalation: recorded treatment plan including planned multi-disciplinary team discussion.

**Discussion**

We previously observed that suspected RTI was the commonest indication for antibiotics in hospitalized adult patients with suspected or proven COVID-19. In this analysis we have examined the detail of antibiotic prescribing within the RTI group and explored factors associated with receipt of an antibiotic prescription. We observed that antibiotics recommended in local guidelines for lower RTI (amoxicillin, doxycycline and amoxicillin/clavulanate) accounted for three of every five antibiotic prescriptions for RTI. Broader-spectrum agents (piperacillin/tazobactam and meropenem) were largely reserved for those in critical care units, reflecting suspected nosocomial/ventilation-associated...
infection. SAPG COVID-19 antibiotic guidance promotes oral antibiotics over IV therapy when clinically appropriate and IV to oral switch when clinical improvement when initial IV therapy is used. Approximately two-thirds of those receiving antibiotics for RTI on wards were receiving oral therapy and one-third of those had switched from IV therapy after a median of 2 days suggesting timely review and rationalization of therapy. Of those prescribed IV therapy on wards on the day of the data collection, the median IV therapy duration was 2 days suggesting prolonged IV antibiotic therapy in ward-based patients was exceptional and indicates adherence to IV to oral switch guidance. Short duration therapy (5 days) for lower RTI was promoted prior to the COVID-19 pandemic and was emphasized again to Antimicrobial Management Teams by SAPG in March 2020 in the context of the pandemic. It is recommended to record the duration of oral antibiotic therapy on the drug prescription chart/electronic record and we observed this in the majority (77.0%) of cases. Recorded planned duration of oral therapy also aligned with national and local guidance, with a median duration of 5 days.

Variables associated with an antibiotic prescription for presumptive lower RTI likely reflects clinical uncertainty and inability to rule out bacterial infection. Those with proven SARS-CoV-2 and probable or definite nosocomial COVID-19 were less likely to be receiving an antibiotic, likely reflecting less clinical uncertainty, rationalization of treatment following review of test results. No differences in antibiotic prescribing for RTI were observed between those in whom decisions were documented for ‘ward level care’ or ‘not for resuscitation’ supporting the operational policy that ‘not for resuscitation’ does not mean ‘not for any treatment’. The importance of antibiotic decision making at the end of life has been the focus of both a recent systematic review and the SAPG Good Practice Recommendations, which emphasize the importance of agreed treatment goals, shared decision making and regular antibiotic review. Further work to better understand therapeutic decision making at end of life in COVID-19 would be useful.

COVID-19 continues to challenge antimicrobial stewardship efforts, with a lack of published evidence to support a role for bacterial coinfection during the early (pre-critical care) phase of SARS-CoV-2. We found CRP to be an independent predictor for an antibiotic prescription for RTI in suspected and proven COVID-19. In contrast to most other respiratory viral infections CRP lacks utility in differentiating bacterial from SARS-CoV-2 infection and its use during the pandemic reflects prescribing practice pre-pandemic. The biomarker procalcitonin (PCT) is not routinely measured outside of critical care in NHS Scotland. PCT is often elevated in the inflammatory response to SARS-CoV-2 as well as in the context of bacterial RTI. Although PCT cannot currently be recommended as a guide to the initiation of antibiotics in the context of COVID-19, there may be value in using it to guide early discontinuation of antibiotics, particularly in critical care patients when used in combination with careful microbiological assessment. Knowledge of the low prevalence of bacterial co-infection, together with rapid

Table 2. Antibiotics prescribed for suspected respiratory tract infection, by ward type and by SARS-CoV-2 result

| Antibiotics prescribed on day of survey | Total number of prescriptions | Percentage of total | Medical and elderly wards | Critical care |
|----------------------------------------|------------------------------|-------------------|---------------------------|--------------|
|                                        |                              |                   | SARS-CoV-2 positive | SARS-CoV-2 negative | SARS-CoV-2 positive | SARS-CoV-2 negative |
| Amoxicillin                            | 85                           | 24.6              | 35                       | 45            | 5                  | 0                  |
| Azithromycin                           | 5                            | 1.4               | 1                        | 2             | 2                  | 0                  |
| Aztreonam                              | 1                            | 0.3               | 0                        | 0             | 1                  | 0                  |
| Ceftriaxone                             | 1                            | 0.3               | 1                        | 0             | 0                  | 0                  |
| Ciprofloxacin                          | 5                            | 1.4               | 1                        | 2             | 2                  | 0                  |
| Clarithromycin                         | 19                           | 5.5               | 5                        | 10            | 3                  | 1                  |
| Amoxicillin/clavulanate                | 52                           | 15.0              | 22                       | 21            | 8                  | 1                  |
| Trimethoprim/sulfamethoxazole          | 9                            | 2.6               | 6                        | 3             | 0                  | 0                  |
| Doxycycline                            | 71                           | 20.5              | 41                       | 30            | 0                  | 0                  |
| Flucloxacillin                         | 2                            | 0.6               | 1                        | 0             | 1                  | 0                  |
| Gentamicin                             | 11                           | 3.2               | 8                        | 3             | 0                  | 0                  |
| Levofloxacin                           | 7                            | 2.0               | 4                        | 2             | 1                  | 0                  |
| Meropenem                              | 16                           | 4.6               | 2                        | 1             | 12                 | 1                  |
| Metronidazole                          | 16                           | 4.6               | 5                        | 10            | 0                  | 1                  |
| Other                                  | 7                            | 2.0               | 0                        | 3             | 2                  | 2                  |
| Piperacillin/tazobactam                | 24                           | 6.9               | 7                        | 6             | 10                 | 1                  |
| Temocillin                             | 4                            | 1.2               | 1                        | 1             | 2                  | 0                  |
| Trimethoprim                           | 0                            | 0.0               | 0                        | 0             | 0                  | 0                  |
| Vancomycin                             | 11                           | 3.2               | 5                        | 2             | 4                  | 0                  |
| Total                                  | 346                          | 100.0             | 145                      | 141           | 53                 | 7                  |

*Patients may have received more than one antibiotic. The name of one antimicrobial was not recorded for one patient (COVID-19 positive and in critical care) receiving an antibiotic on the day of the survey for a respiratory indication.
SARS-CoV-2 diagnosis including point of care testing, should reduce clinical uncertainty in antibiotic decision-making and the use of corticosteroids in patients requiring supplemental oxygen therapy offers an effective therapeutic advance for hospitalized patients. Unfortunately, a proportion of high-risk patients with COVID-19 will deteriorate and nosocomial infection, particularly ventilator-associated pneumonia, will continue to be a significant challenge. Judicious use of antibiotics in ward patients and careful microbiology isolate-driven prescribing in the critical care setting should limit unnecessary escalation of antimicrobials and limit the future risk of antimicrobial-resistant and opportunistic infections.

Although we have demonstrated evidence supporting good antibiotic stewardship in the context of suspected RTI in COVID-19, antibiotic use prevalence in the absence of evidence of bacterial co-infection remains a concern. Our survey was also limited as it did not include microbiological data, but data collectors did record whether prescribing was microbiologically directed or empirical. The rates of observed empirical antibiotic prescribing for RTI highlights the importance of ongoing local and national initiatives to reinforce stewardship in the COVID-19 context and beyond. Clinical review and decision making, and early use of microbiological diagnostics, are central to limit unnecessary antibiotic therapy and other antibiotic-related harm.

Acknowledgements
The authors would like to thank health board Antimicrobial Management Teams and clinicians in the participating hospitals who coordinated the survey and collected data: Ursula Altmeyer, Natalie Arandia, Francisca Bartiotti Matos, Vhairi Bateman, Andrew Blunsum, Kevin Blythe, Sarah Bowers, Rhona Boyle, Adam Brown, Mark Brown, Niamh Burns, Robyn Canham, Sadman Chowdhury, Katherine Cobb, Alison Cockburn, Malcolm Daniel, Peter Davies, Gilchrist Docherty, Thomas Downs, Morgan

---

### Table 3. Antibiotic use in patients with respiratory tract infection (RTI) on day of survey

| Characteristic                              | Medical and elderly wards (n = 697) | Critical care wards (n = 121) | Total (n = 818) |
|--------------------------------------------|------------------------------------|------------------------------|-----------------|
|                                           | Total surveyed patients | Total surveyed patients with characteristic | %     | Total surveyed patients | Total surveyed patients with characteristic | %     | Total surveyed patients | Total surveyed patients with characteristic | %     |
| Antibiotic(s) for RTI                     | 697                  | 225                           | 32.3             | 121                 | 47                          | 38.8             | 818                  | 272                           | 33.3             |
| Antibiotic(s) for RTI (% all treated)     | 314                  | 225                           | 71.7             | 54                   | 47                          | 87.0             | 368                  | 272                           | 73.9             |
| Empirical antibiotic for RTI              | 224                  | 213                           | 95.1             | 47                   | 36                          | 76.6             | 271                  | 249                           | 91.9             |
| SARS-CoV-2 positive and RTI antibiotic(s) | 225                  | 117                           | 52.0             | 47                   | 43                          | 91.5             | 272                  | 160                           | 58.8             |
| Single or multiple antibiotic(s) for RTI  |                      |                               |                  |                      |                             |                  |                      |                                |                  |
| Single antibiotic                          | 225                  | 170                           | 75.6             | 46                   | 33                          | 71.7             | 271                  | 203                           | 74.9             |
| Dual antibiotics                           | 225                  | 49                            | 21.8             | 46                   | 12                          | 26.1             | 271                  | 61                            | 22.5             |
| Triple antibiotics                         | 225                  | 6                             | 2.7              | 46                   | 1                           | 2.2              | 271                  | 7                             | 2.6              |
| Total antibiotics prescribed (all indications) | 420 | 70                                      |                  |                      |                             |                  |                      |                                |                  |
| Total antibiotics prescribed for RTI       | 286                  |                               |                  |                      |                             |                  |                      |                                |                  |
| Route of administration of all antibiotics|                      |                               |                  |                      |                             |                  |                      |                                |                  |
| Oral                                       | 283                  | 174                           | 61.5             | 59                   | 6                           | 10.2             | 342                  | 180                           | 52.6             |
| IV                                         | 283                  | 109                           | 38.5             | 59                   | 53                          | 89.8             | 342                  | 162                           | 47.4             |
| No. receiving IV antibiotic(s)             | 223                  | 80                            | 35.9             | 45                   | 42                          | 93.3             | 268                  | 122                           | 45.5             |
| No. Treated with oral therapy only         | 223                  | 143                           | 64.1             | 45                   | 3                           | 6.7              | 268                  | 146                           | 54.5             |
| No. receiving oral following IV antibiotic| 135                  | 48                            | 35.6             | 2                    | 1                           | 50               | 146                  | 49                            | 33.6             |
| Median duration of IV antibiotic (at time of survey) | 2 days (range 1–26, IQR 2–3) | 3 days (range 1–13, IQR 2–6) | 2 days (range 1–26, IQR 2–4) |
| Median duration of IV antibiotic prior to oral for RTI antibiotics | 2 days (range <1–14, IQR 1–3) | 8 day (range 2–18, IQR 5–12) | 2 days (range <1–18, IQR 1–4) |
| No. patients where proposed duration of oral antibiotic was recorded for RTI | 112/146 (76.7%) | NA | 112/146 (76.7%) |
| Median recorded planned duration of oral antibiotic for RTI | 5 days (range 2–10, IQR 3–7) | NA | 5 days (range 2–10, IQR 3–7) |

NA, not applicable.
**Table 4.** Univariate logistic regression analysis of factors associated with either antibiotic prescribing for respiratory tract or no antibiotic prescribing on the day of survey

| Risk factor theme/risk factor | Category | Odds ratio (OR) | OR 95% Lower CI | OR 95% Upper CI | Category P value | Risk factor P value |
|-----------------------------|----------|----------------|-----------------|----------------|-----------------|-------------------|
| **COVID-19 status**         |          |                |                 |                |                 |                   |
| SARS-CoV-2 test result      | Negative*| 1.00           |                 |                |                 |                   |
|                             | Positive | 0.50           | 0.32            | 0.78           | 0.003           | 0.003             |
| Probable/definite nosocomial| No*      | 1.00           |                 |                |                 |                   |
| COVID-19 (>day 8)           | Yes      | 0.24           | 0.14            | 0.43           | <0.001          | <0.001            |
| Positive SARS-CoV-2 test result prior to admission | No* | 1.00 |                 |                |                 |                   |
|                             | Yes      | 1.40           | 0.68            | 2.89           | 0.36            |                   |
| Positive SARS-CoV-2 test from admission to day 7 | No* | 1.00 |                 |                |                 |                   |
|                             | Yes      | 0.86           | 0.61            | 1.21           | 0.40            | 0.40              |
| **Demographics**            |          |                |                 |                |                 |                   |
| Age                         | Cont.    | 0.99           | 0.98            | 1.00           | 0.01            | 0.01              |
| Sex                         | Female*  | 1.00           |                 |                |                 |                   |
|                             | Male     | 0.92           | 0.66            | 1.29           | 0.62            | 0.62              |
| **Location**                |          |                |                 |                |                 |                   |
| Care home resident          | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 1.03           | 0.63            | 1.69           | 0.89            | 0.89              |
| Ward type                   | Critical care* | 1.00 |                 |                |                 |                   |
|                             | Elderly | 0.42           | 0.21            | 0.84           | 0.02            |                   |
|                             | Medical | 0.94           | 0.60            | 1.45           | 0.77            | 0.04              |
| **Length of stay from admission to survey** |          |                |                 |                |                 |                   |
| Length of stay              | Cont.    | 0.97           | 0.96            | 0.99           | 0.008           | 0.008             |
| **Comorbidities**           |          |                |                 |                |                 |                   |
| Asthma                      | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 1.65           | 0.99            | 2.74           | 0.06            | 0.06              |
| Cardiovascular disease      | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 1.00           | 0.70            | 1.40           | 0.96            | 0.96              |
| COPD/Chronic lung disease   | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 2.59           | 1.86            | 3.60           | <0.001          | <0.001            |
| Diabetes                    | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 0.56           | 0.39            | 0.79           | 0.001           | 0.001             |
| Hypertension                | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 0.96           | 0.63            | 1.46           | 0.85            | 0.85              |
| Immunocompromised           | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 1.22           | 0.74            | 1.99           | 0.44            | 0.44              |
| Long term renal dialysis    | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 0.82           | 0.30            | 2.27           | 0.71            | 0.71              |
| Morbid obesity              | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 1.00           | 0.57            | 1.76           | 1.00            | 1.00              |
| Other chronic illness       | No*      | 1.00           |                 |                |                 |                   |
|                             | Yes      | 0.98           | 0.73            | 1.32           | 0.90            | 0.90              |
| Treatment escalation        | DNAR     | No*            | 1.00           |                 |                 |                   |
|                             | Yes      | 0.70           | 0.49            | 1.02           | 0.07            | 0.07              |
| **Diagnostics/clinical signs** |          |                |                 |                |                 |                   |
| Chest x-ray                 | Normal* | 1.00           |                 |                |                 |                   |
|                             | Abnormal| 2.14           | 1.49            | 3.08           | <0.001          | <0.001            |
| CRP                          | 0–99 mg/L| 1.00           |                 |                |                 |                   |

Continued
Table 4. Continued

| Risk factor theme/risk factor | Category² | Odds ratio (OR) | OR 95% Lower CI | OR 95% Upper CI | Category P value | Risk factor P value |
|------------------------------|-----------|----------------|-----------------|-----------------|------------------|-------------------|
| Sputum                       | ≥100 mg/L | 1.79           | 1.32            | 2.41            | <0.001           | <0.001            |
|                              | Normal*   | 1.00           |                 |                 |                  |                   |
|                              | Purulent or bloody | 2.33 | 1.54           | 3.54            | <0.001           | <0.001            |

COPD, chronic obstructive pulmonary disease and other chronic lung disease; DNAR, do not attempt cardiopulmonary resuscitation order; CRP, C-reactive protein. Modelling excludes records with unknown antimicrobial status, COPD/chronic lung disease, morbid obesity, treatment for high blood pressure, cardiovascular disease, immunocompromised as per HPS/SG advice, other chronic illness and DNAR leaving 694 rows for inclusion in the analysis.

²An asterisk denotes the reference category.

Table 5. Multivariable analysis of factors associated with antibiotic prescribing for a respiratory tract infection indication²,b

| Variable                                        | OR    | Lower 95% CI | Upper 95% CI | Wald test P value |
|-------------------------------------------------|-------|--------------|--------------|-------------------|
| SARS-CoV-2 positive                             | 0.51  | 0.33         | 0.81         | 0.005             |
| COPD/chronic lung disease                       | 2.40  | 1.66         | 3.46         | <0.001            |
| Diabetes                                        | 0.58  | 0.40         | 0.84         | 0.006             |
| CRP ≥ 100 mg/L                                  | 1.83  | 1.28         | 2.61         | 0.001             |
| Abnormal chest X-ray                            | 1.88  | 1.22         | 2.90         | 0.005             |
| Purulent or bloody sputum                       | 1.85  | 1.17         | 2.91         | 0.005             |
| Probable or definite nosocomial COVID-19         | 0.43  | 0.24         | 0.74         | 0.004             |

²Patients who were prescribed antibiotics for other indications were excluded from this analysis.

³Modelling excludes records with unknown antimicrobial status, COPD/chronic lung disease, morbid obesity, treatment for high blood pressure, cardiovascular disease, immunocompromised as per HPS/SG advice, other chronic illness and DNAR leaving 694 rows for inclusion in the analysis.

²An asterisk denotes the reference category.

Evans, Eoghan Farmer, Leonard Farrugia, Jude Fleming, Stewart Gallagher, Claire Gilmore, Anna Graham, Jane Gravil, Hudson Guyver, Phil Henderson, Lisa Hutton, Katherine Hylands, Su Su Htwe, Caitlin Hughes, Callum Innes, Alistair James, Cameron Kay, Elena Kay, Heather Kennedy, Laura Knox, Nicole Lou, Andrew Lazarowicz, Eilidh Lynch, Alison MacDonald, Mhairi Mactier, Sumera Mahmood, Kaitlin Mayne, Catriona McBride, Dayni McConnell, Steve McCormick Marcus McClean Fiona McDonald, Dominic McGovern, A McGucken, Andrew McKay, Ja McEwan, Lara Mitchell, Olivia Morton, Samantha Ong, Dominic Owtram, Espe Palenzuela, Rebecca Petrie, Carol Philip, Kimberley Philip, Niketa Piatt, Nathaniel Quail, Emily Reid, Stuart Reid, Mathew Robinson, Laura Quate, K. Rajasegaran, Jen Rollo, Claire Rooney, Kevin Rooney, Maggie Rostron, Chris Salt, Andrew Smart, Lee Stewart, Harrison Stubbs, Bobby Sykes, Daniel Taylor-Sweet, Horriet Turner, Jennifer Wardal, Emily Wright, Caitlin Young. Thanks also to Marion Pirie, SAPG Project Officer for supporting all communications associated with the study.

Funding
This study was supported by the Scottish Antimicrobial Prescribing Group, which is funded by the Scottish Government.

Transparency declarations
None to declare.

References
1. Health Protection Scotland. National point prevalence survey of healthcare associated infection and antimicrobial prescribing. 2016. https://www.hps.scot.nhs.uk/web-resources-container/national-point-prevalence-survey-of-healthcare-associated-infection-and-antimicrobial-prescribing-2016/.
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395: 1054–62.
3. Doherty AB, Harrison EM, Green CA, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational study cohort. BMJ 2020;369: m1985.
4. Scottish Antimicrobial Prescribing Group. SAPG response to COVID-19. https://www.sapg.scot/about-us/latest-updates/sapg-response-to-covid-19/.
5. Seaton RA, Gibbons CL, Cooper L, et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. JInfection 2020;81: 952–60.

Author contributions
R.A.S., J.S. and W.M. conceived the study and its design, had full access to the data, and take responsibility for the integrity of the data and accuracy of the analysis. L.C., C.L.G. and R.A.S. designed and conducted data analyses. D.G., S.D., S.B., D.J., B.C-K., K.H., R.M. and D.G. organized and collected data. R.A.S., J.S., W.M., L.C. and C.G. drafted the manuscript. All authors critically revised the drafted manuscript and approved the submitted manuscript.
6 Public Health Scotland. Hospital onset COVID-19 cases in Scotland. https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/.

7 Fairweather J, Cooper L, Sneddon et al. Antimicrobial use at the end of life: a scoping review. BMJ Support Palliat Care 2020; bmjspcare-2020-002558.

8 Seaton RA, Fenning S, Cooper L et al. Antibiotic use towards the end of life: development of good practice recommendations. BMJ Support Palliat Care 2021; bmjspcare-2020-002732.

9 Langford BJ, So M, Raybardenh S et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020; 6: 1622–9.

10 Lansbury L, Lim B, Baskaran V et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020; 81: 266–75.

11 Karami Z, Knoop BT, Dofferhoff ASM et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multi-centre retrospective cohort study in The Netherlands. Infect Dis 2021; 53: 102–10.

12 Malik P, Patel U, Mehta D et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med 2020; bmjebm-2020-111536.

13 Hellyer TP, Mantle T, Dark P. How to optimise duration of antibiotic treatment in patients with sepsis? Brit Med J 2020; 371: m4357.

14 The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. New Engl J Med 2021; 384: 693–704.

15 Knight SR, Ho A, Pius R et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 2020; 370: m3339.